Company: RVRC
Filing Date: 2025-12-12
Form Type: S-1/A
Source: 0001213900-25-121070
Chunk: 220

Company: Revium Rx.
Filing Date: 2025-12-12
Form: S-1/A
Chunk 220
---
 expense to the actual tax expense: |

The main reconciling
item between the statutory tax rate of the Company and the effective tax rate is the recognition of valuation allowance in respect of
deferred taxes relating to accumulated net operating losses carried forward due to the uncertainty of the realization of such deferred
taxes.

<div align='center'>F-30</div>

REVIUM RX.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

U.S. dollars in thousands, except share and per share data

NOTE 9 – TAXES ON INCOME (Cont.)

|                                                      |     |   Successor |       |   |     | Predecessor |       |   |     |              |      |   |
|                                                      |     | December 31 |       |   |     |    23 July, |       |   |     | December 31, |      |   |
|                                                      |     |        2024 |       |   |     |        2024 |       |   |     |         2023 |      |   |
| Net loss, as reported in the consolidated statements 
 of comprehensive loss                                |     |             | 2,084 |   |     |             | 1,421 |   |     |              |  987 |   |
| Statutory tax rate                                   |     |             |    21 | % |     |             |    23 | % |     |              |   23 | % |
| Computed “expected” tax income                       |     |             |   437 |   |     |             |   326 |   |     |              |  227 |   |
| Valuation allowance                                  |     |             |  (437 | ) |     |             |  (326 | ) |     |              | (227 | ) |
| Taxes on income                                      |     |             |     - |   |     |             |     - |   |     |              |    - |   |

NOTE 10 – COMMITMENTS AND CONTINGENCIES

Predecessor:

The Predecessor’s
research is conducted at the Hebrew University (subject to license and research agreements) in Professor Bernholtz Yehezkel’s laboratory,
and the drug development activity is conducted through subcontractors.

The Predecessor
has signed an option agreement for an exclusive license for the technology with “Yissum Research Development Company of the Hebrew
University of Jerusalem Ltd.” (“Yissum”), the